Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 26, Number 8—August 2020
Research

Analysis of MarketScan Data for Immunosuppressive Conditions and Hospitalizations for Acute Respiratory Illness, United States

Manish PatelComments to Author , Jufu Chen, Sara Kim, Shikha Garg, Brendan Flannery, Zaid Haddadin, Danielle Rankin, Natasha Halasa, H. Keipp Talbot, and Carrie Reed
Author affiliations: Centers for Disease Control and Prevention, Atlanta, Georgia, USA (M. Patel, J. Chen, S. Kim, S. Garg, B. Flannery, C. Reed); Vanderbilt University, Nashville, Tennessee, USA (Z. Haddadin, D. Rankin, N. Halasa, H. Keipp Talbot)

Main Article

Table 3

Codes for influenza vaccine used in analysis of MarketScan data for immunosuppressive conditions and hospitalizations for acute respiratory illness, United States

CPT no.* Vaccine type
90653 Influenza virus vaccine, inactivated, subunit, adjuvanted, for intramuscular use
90654 influenza, seasonal, intradermal, preservative free
90655 Influenza virus vaccine, split virus, no preservative, for children 6–35 mo of age, for intramuscular use
90656 Influenza virus vaccine, split virus, no preservative, for use in persons >3 y of age, for intramuscular use
90657 Influenza virus vaccine, split virus, for children 6–35 mo of age, for intramuscular use
90658 Influenza virus vaccine, split virus, for use in persons >3 y of age, for intramuscular use
90659 Influenza, whole
90660 Influenza virus vaccine, live, for intranasal use
90661 Influenza virus vaccine, derived from cell cultures, subunit, preservative and antimicrobial drug free, for intramuscular use
90662 Influenza, high dose seasonal
90663 Influenza virus vaccine, pandemic H1N1
90664 Influenza virus vaccine, pandemic formulation, live, for intranasal use
90666 Influenza virus vaccine, pandemic formulation, split virus, preservative free, for intramuscular use
90667 Influenza virus vaccine, pandemic formulation, split virus, adjuvanted, for intramuscular use
90668 Influenza virus vaccine, pandemic formulation, split virus, for intramuscular use
90724 Influenza, unspecified formulation
90470 H1N1 immunization administration (intramuscular, intranasal)
90672 Influenza virus vaccine, quadrivalent, live, for intranasal use
90673 Influenza virus vaccine, trivalent, derived from recombinant DNA (recombinant influenza vaccine 3), hemagglutnin protein only, preservative and antimicrobial drug free, for intramuscular use
90685 Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children 6–35 mo of age, for intramuscular use
90686 Influenza virus vaccine, quadrivalent, split virus, preservative free, when administered to children >3 y of age, for intramuscular use
90687 Influenza virus vaccine, quadrivalent, when administered to children 6–35 mo of age, for intramuscular use (not recognized by Medicare)
90688 Influenza virus vaccine, quadrivalent, when administered to persons >3 y, for intramuscular use (not recognized by Medicare)

*CPT, Current Procedural Terminology.

Main Article

Page created: April 29, 2020
Page updated: July 17, 2020
Page reviewed: July 17, 2020
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external